A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial) | SpringerLink
Olaparib for Pancreatic Cancer with BRCA Mutations - NCI
FORCE Blog | New PARP Inhibitor Approval for Pancreatic Cancer
Lynparza® for the Maintenance Treatment of Patients with Germline BRCA-Mutated Metastatic Adenocarcinoma of the Pancreas
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Cancer Trial Results
ASCO GI 2021: Results From the Phase 3 POLO Trial
POLO: Olaparib as maintenance treatment for metastatic pancreatic cancer - YouTube
Cancers | Free Full-Text | Targeting DNA Damage Repair Mechanisms in Pancreas Cancer
POLO Trial Shows Maintenance Olaparib Improves PFS in Metastatic Pancreatic Cancer - The ASCO Post
LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
Olaparib in Metastatic Pancreatic Cancer
The POLO Trial is Great, But Probably Not Practice-Changing
JNCCN study evaluates cost-effectiveness of o | EurekAlert!
Pancreatic cancer treatment: Polo trial for Maintenance Lynparza (olaparib)
LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
Maintenance Olaparib vs Placebo in Germline BRCA-Mutated Metastatic Pancreatic Cancer - The ASCO Post
ASCO GI 2021: Results From the Phase 3 POLO Trial
LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
ASCO GI 2021: Results From the Phase 3 POLO Trial
Olaparib in Metastatic Pancreatic Cancer
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Cancer Trial Results
Cancer Trial Results
